Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CHKA | P35790 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813208 | 0.85 | CHEK1 (0.35) | CHEK1 | |
| SCHEMBL4815094 | 0.82 | KDR (0.43) | KDRCHEK1KCNH2CHKA | |
| SCHEMBL4809883 | 0.79 | DGAT1 (0.33) | — | |
| SCHEMBL4816240 | 0.69 | KDR (0.69) | KDRCHEK1KCNH2KITFLT1 | |
| SCHEMBL4814003 | 0.67 | CHEK1 (0.36) | KDRCHEK1 | |
| SCHEMBL23533522 | 0.66 | SUCNR1 (0.35) | — | |
| SCHEMBL4813087 | 0.66 | CHEK1 (0.42) | KDRCHEK1FLT4 | |
| SCHEMBL15312046 | 0.62 | SRC (0.34) | KDRCHKAKIT | |
| SCHEMBL18177890 | 0.62 | TSHR (0.72) | KDRCHEK1CHKA | |
| SCHEMBL4810703 | 0.61 | DGAT1 (0.42) | KDRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | KDR 1024/4885CHEK1 73/4885KCNH2 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.